Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes | Zendy

Daniel R. Quast | Zendy; Nina Schenker | Zendy; Björn A. Menge | Zendy; Michael A. Nauck | Zendy; Christoph Kapitza | Zendy; Juris J. Meier | Zendy

Open Access

Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes

Author(s) -

Daniel R. Quast,

Nina Schenker,

Björn A. Menge,

Michael A. Nauck,

Christoph Kapitza,

Juris J. Meier

Publication year - 2020

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc20-0720

Subject(s) - lixisenatide , medicine , gastric emptying , liraglutide , gastroenterology , reflux , gastric acid , type 2 diabetes , endocrinology , diabetes mellitus , stomach , disease

Short-acting glucagon-like peptide 1 receptor agonists (GLP-1 RAs) decelerate gastric emptying more than long-acting GLP-1 RAs. Delayed gastric emptying is a risk factor for gastroesophageal reflux disease. We aimed to measure esophageal reflux and function as well as gastric emptying and acid secretion during treatment with short-acting (lixisenatide) and long-acting (liraglutide) GLP-1 RAs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research